Related Experiment Video

Updated: Apr 17, 2026

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.6K

Nonsense suppression therapies in ocular genetic diseases

Xia Wang1, Cheryl Y Gregory-Evans

  • 1Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, V5Z 3N9, Canada, xw09@mail.ubc.ca.

Cellular and Molecular Life Sciences : CMLS
|February 6, 2015
PubMed

Insights

Premature termination codons (PTCs) trigger nonsense-mediated decay (NMD) or truncated proteins, causing genetic diseases. Nonsense suppression therapy offers a potential treatment by enabling readthrough of PTCs to restore functional proteins.

Area of Science:

  • Genetics
  • Molecular Biology
  • Ophthalmology

Background:

  • Nonsense mutations create premature termination codons (PTCs).
  • PTCs lead to mRNA degradation via nonsense-mediated decay (NMD) or truncated, non-functional proteins.
  • PTCs are implicated in various inherited diseases, including ocular disorders.

Purpose of the Study:

  • To review mechanisms distinguishing normal termination from PTCs.
  • To summarize current understanding of NMD.
  • To explore the interplay between PTCs and NMD, and suppression therapies for PTC-mediated ocular diseases.

Main Methods:

  • Literature review of PTC and NMD mechanisms.
  • Analysis of existing NMD models.
  • Examination of suppression therapy strategies in ocular disease models.

Main Results:

  • Detailed mechanisms for differentiating normal vs. premature termination.
  • Insights into the dynamic processes and crosstalk between PTCs and NMD.
  • Overview of therapeutic approaches for PTC-induced ocular conditions.

Conclusions:

  • Understanding PTC and NMD complexity is crucial for developing effective treatments.
  • Nonsense suppression therapy holds promise for genetic disorders caused by PTC mutations.
  • Further research into PTC-NMD interactions can advance therapeutic strategies for inherited diseases.

More Related Videos

The Measurement and Treatment of Suppression in Amblyopia08:34

The Measurement and Treatment of Suppression in Amblyopia

Published on: December 14, 2012

50.8K
Intravitreal Injections in the Ovine Eye03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

4.4K

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
252
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
5.0K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K